Janssen Research & Development
3210 Merryfield Row
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
130 articles about Janssen Research & Development
MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
MorphoSys AG announced that its licensee Janssen Research & Development, LLC. has announced it received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the expanded use of Tremfya for the treatment of adult patients with active psoriatic arthritis in the European Union.
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.
nference Enters into an R&D Data Science Strategic Partnership with Janssen
Multi-year research collaboration and software agreement reimagines the discovery and clinical development of medicines through data sciences
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX
UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen
Focused Agreement is on Therapeutic Area of Mutual Interest
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.
One Mind Announces Request for Proposals for Five New $250,000 Rising Star Research Awards
Given the growing challenges of addressing brain illness and injury, One Mind, in collaboration with Janssen Research & Development LLC, Otsuka Pharmaceuticals, Kaiser Permanente, the Gifford Foundation, and Bettina Bryant, is offering up to five Rising Star Research Awards in 2019.
Dr. Guislain Museum and Janssen Seek Global Nominations for Annual "Breaking the Chains of Stigma" Award
The Dr. Guislain Museum and Janssen Research & Development, LLC, today announced the global nominations for the Dr. Guislain "Breaking the Chains of Stigma" Award can now be submitted at www.drguislainaward.org until 14 April, 2019.
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has reported that the U.S. Food and Drug Administration has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.
On Tuesday, a U.S. Food and Drug Administration advisory panel overwhelmingly supported approval of the nasal spray treatment.
Johnson & Johnson's Potential Depression Blockbuster Esketamine Shows Promise in Phase II Study
12/29/2017The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo.
Janssen R&D Establishes First-Of-Its-Kind Mobile Medication And Data Management Technology Platform For Industry Use
Janssen R&D Submits New Drug Application To FDA For The First Darunavir-Based Single Tablet Regimen For The Treatment Of HIV-1
Janssen R&D Release: New Two-Year TREMFYA (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance
Janssen R&D Release: U.S. FDA Grants Priority Review Of XARELTO (Rivaroxaban) sNDA For A 10 Mg Dose To Reduce The Risk Of Recurrent Venous Thromboembolism (VTE)
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Yea
Janssen R&D Release: Daratumumab Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma
MorphoSys AG Announces That Its Licensee Janssen R&D Reported Updates On The Development Of Guselkumab
Janssen R&D Submits Supplemental New Drug Application To U.S. FDA Based On EINSTEIN CHOICE Data, Which Showed Superiority With XARELTO (Rivaroxaban) Versus Aspirin In Reducing Risk Of Recurrent Venous Thromboembolism (VTE), With Low Rates Of Major Bleedin
The Castleman Disease Collaborative Network Announces A Research Collaboration With Janssen R&D To Conduct A Proteomics Study Of Idiopathic Multicentric Castleman Disease